Geron (GERN)
(Delayed Data from NSDQ)
$4.56 USD
+0.05 (1.11%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $4.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.56 USD
+0.05 (1.11%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $4.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Geron (GERN) Begins Phase III Myelofibrosis Study on Imetelstat
by Zacks Equity Research
Geron (GERN) is evaluating its lead pipeline candidate, imetelstat, in late-stage studies for refractory myelofibrosis and myelodysplastic syndromes.
Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Geron (GERN) delivered earnings and revenue surprises of -20.00% and 44.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Enlivex (ENLV) This Earnings Season?
by Zacks Equity Research
Investors will be keen on pipeline updates when Enlivex Therapeutics (ENLV) reports results for the three months ending Sep 30, 2020.
Is a Disappointment in Store for Tilray's (TLRY) Q3 Earnings?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports third-quarter 2020 results.
Qorvo, Nikola, BMY, MyoKardia and Geron as Zacks Bull and Bear of the Day
by Zacks Equity Research
Qorvo, Nikola, BMY, MyoKardia and Geron as Zacks Bull and Bear of the Day
Is a Disappointment in Store for Zosano (ZSAN) Q3 Earnings?
by Zacks Equity Research
Investors will be keen on updates on Qtrypta when Zosano (ZSAN) reports Q3 results.
Mylan (MYL) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q3 results.
Is a Beat in the Cards for Bristol-Myers' (BMY) Q3 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports third-quarter 2020 results.
What's in the Cards for Regeneron's (REGN) Q3 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports third-quarter 2020 results.
Incyte (INCY) to Post Q3 Earnings: Will Jakafi Drive Results?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports third-quarter 2020 results.
Geron (GERN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Geron (GERN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Geron (GERN) Looks Good: Stock Adds 6.5% in Session
by Zacks Equity Research
Geron (GERN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Will Geron (GERN) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Geron Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Geron has been struggling lately, but the selling pressure may be coming to an end soon
Geron Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Geron has been struggling lately, but the selling pressure may be coming to an end soon.
Is Geron (GERN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GERN) Outperforming Other Medical Stocks This Year?
Zealand Announces Dosing Initiation in Type 2 Diabetes Study
by Zacks Equity Research
Zealand's (ZEAL) partner, Boehringer Ingelheim, is developing BI 456906, a long-acting GLP-1/glucagon dual agonist, as a treatment for obesity and type 2 diabetes.
Geron's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Geron.
Is Geron (GERN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GERN) Outperforming Other Medical Stocks This Year?
Dynavax's Partner Doses First Patient in Coronavirus Study
by Zacks Equity Research
Dynavax's (DVAX) China-based partner initiates dosing in a phase I study evaluating a COVID-19 vaccine using the company's proprietary CpG 1018 adjuvant. Preliminary data are expected in August.
Implied Volatility Surging for Geron Corporation (GERN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Geron Corporation (GERN) stock based on the movements in the options market lately.
Moving Average Crossover Alert: Geron
by Zacks Equity Research
Geron Corporation (GERN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Dynavax Closes Enrollment in Renal Disease Study on Heplisav-B
by Zacks Equity Research
Dynavax (DVAX) is developing its hepatitis B vaccine, Heplisav-B, in patients with end-stage renal disease undergoing hemodialysis in a phase I study.
How Geron Corporation (GERN) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Geron Corporation (GERN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.